Aminologics Co.Ltd (074430) - Total Liabilities
Based on the latest financial reports, Aminologics Co.Ltd (074430) has total liabilities worth ₩30.52 Billion KRW (≈ $20.68 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aminologics Co.Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how Aminologics Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See Aminologics Co.Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Aminologics Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Aminologics Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
Turkey | TL5.00 Billion |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
Taiwan | NT$643.75 Million |
|
SinterCast AB
ST:SINT
|
Sweden | Skr37.80 Million |
|
Freightos Limited Ordinary shares
NASDAQ:CRGO
|
USA | $19.94 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM183.81 Million |
|
OFS Credit Company Inc
NASDAQ:OCCI
|
USA | $117.96 Million |
|
Concrete Engineering Products
KLSE:8435
|
Malaysia | RM52.45 Million |
|
Thai Wah Public Company Limited
BK:TWPC
|
Thailand | ฿3.06 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Aminologics Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 074430 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aminologics Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aminologics Co.Ltd (2008–2025)
The table below shows the annual total liabilities of Aminologics Co.Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩28.18 Billion ≈ $19.10 Million |
+453.31% |
| 2024-12-31 | ₩5.09 Billion ≈ $3.45 Million |
+56.39% |
| 2023-12-31 | ₩3.26 Billion ≈ $2.21 Million |
-22.04% |
| 2022-12-31 | ₩4.18 Billion ≈ $2.83 Million |
-28.57% |
| 2021-12-31 | ₩5.85 Billion ≈ $3.96 Million |
-10.98% |
| 2020-12-31 | ₩6.57 Billion ≈ $4.45 Million |
+10.95% |
| 2019-12-31 | ₩5.92 Billion ≈ $4.01 Million |
+61.32% |
| 2018-12-31 | ₩3.67 Billion ≈ $2.49 Million |
-13.19% |
| 2017-12-31 | ₩4.23 Billion ≈ $2.87 Million |
-5.56% |
| 2016-12-31 | ₩4.48 Billion ≈ $3.03 Million |
-33.68% |
| 2015-12-31 | ₩6.75 Billion ≈ $4.58 Million |
-0.47% |
| 2014-12-31 | ₩6.78 Billion ≈ $4.60 Million |
-12.81% |
| 2013-12-31 | ₩7.78 Billion ≈ $5.27 Million |
-63.30% |
| 2012-12-31 | ₩21.20 Billion ≈ $14.37 Million |
-7.42% |
| 2011-12-31 | ₩22.90 Billion ≈ $15.52 Million |
-3.59% |
| 2010-12-31 | ₩23.75 Billion ≈ $16.09 Million |
+72.46% |
| 2008-12-31 | ₩13.77 Billion ≈ $9.33 Million |
-- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more